To include your compound in the COVID-19 Resource Center, submit it here.

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from a Phase II trial of the company’s glucokinase activator to treat Type I diabetes could portend further success in a planned pivotal study. The company hopes the therapy, TTP399, can become a first-in-class oral adjunctive treatment to insulin for Type I diabetics.

vTv Therapeutics Inc. (NASDAQ:VTVT) said Monday that TTP399 significantly reduced

Read the full 673 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers